...
search icon
pgen-img

Precigen Inc, Common Stock

PGEN

NASDAQ

$1.27

-$0.03

(-2.31%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$374.87M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
904.74K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.68
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.65 L
$1.93 H
$1.27

About Precigen Inc, Common Stock

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePGENSectorS&P500
1-Week Return7.63%3.54%-0.58%
1-Month Return36.11%7.51%1.89%
3-Month Return50.33%-0.85%3.24%
6-Month Return-21.6%-1.67%10.09%
1-Year Return-14.19%5.2%22.09%
3-Year Return-48.37%13.08%35.68%
5-Year Return-76.22%44.4%83.47%
10-Year Return-95.77%111.45%200.41%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue90.72M103.18M103.87M26.91M6.22M[{"date":"2019-12-31","value":87.34,"profit":true},{"date":"2020-12-31","value":99.33,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":25.91,"profit":true},{"date":"2023-12-31","value":5.99,"profit":true}]
Cost of Revenue61.40M55.51M58.38M6.34M6.12M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":90.41,"profit":true},{"date":"2021-12-31","value":95.09,"profit":true},{"date":"2022-12-31","value":10.32,"profit":true},{"date":"2023-12-31","value":9.97,"profit":true}]
Gross Profit29.32M47.66M45.49M20.57M106.00K[{"date":"2019-12-31","value":61.51,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":95.43,"profit":true},{"date":"2022-12-31","value":43.16,"profit":true},{"date":"2023-12-31","value":0.22,"profit":true}]
Gross Margin32.32%46.20%43.79%76.44%1.70%[{"date":"2019-12-31","value":42.28,"profit":true},{"date":"2020-12-31","value":60.43,"profit":true},{"date":"2021-12-31","value":57.29,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.23,"profit":true}]
Operating Expenses202.72M133.35M124.26M95.18M84.18M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":65.78,"profit":true},{"date":"2021-12-31","value":61.3,"profit":true},{"date":"2022-12-31","value":46.95,"profit":true},{"date":"2023-12-31","value":41.53,"profit":true}]
Operating Income(173.40M)(85.68M)(78.78M)(74.61M)(88.92M)[{"date":"2019-12-31","value":-17340200000,"profit":false},{"date":"2020-12-31","value":-8568300000,"profit":false},{"date":"2021-12-31","value":-7877500000,"profit":false},{"date":"2022-12-31","value":-7460600000,"profit":false},{"date":"2023-12-31","value":-8892300000,"profit":false}]
Total Non-Operating Income/Expense(49.08M)(34.30M)(36.84M)(12.00M)(4.67M)[{"date":"2019-12-31","value":-4908000000,"profit":false},{"date":"2020-12-31","value":-3430000000,"profit":false},{"date":"2021-12-31","value":-3683600000,"profit":false},{"date":"2022-12-31","value":-1200100000,"profit":false},{"date":"2023-12-31","value":-467000000,"profit":false}]
Pre-Tax Income(208.69M)(103.86M)(96.92M)(79.97M)(96.36M)[{"date":"2019-12-31","value":-20868700000,"profit":false},{"date":"2020-12-31","value":-10385500000,"profit":false},{"date":"2021-12-31","value":-9692500000,"profit":false},{"date":"2022-12-31","value":-7996600000,"profit":false},{"date":"2023-12-31","value":-9636200000,"profit":false}]
Income Taxes(930.00K)(82.00K)(160.00K)(189.00K)(458.00K)[{"date":"2019-12-31","value":-93000000,"profit":false},{"date":"2020-12-31","value":-8200000,"profit":false},{"date":"2021-12-31","value":-16000000,"profit":false},{"date":"2022-12-31","value":-18900000,"profit":false},{"date":"2023-12-31","value":-45800000,"profit":false}]
Income After Taxes(207.76M)(103.77M)(96.77M)(79.78M)(95.90M)[{"date":"2019-12-31","value":-20775700000,"profit":false},{"date":"2020-12-31","value":-10377300000,"profit":false},{"date":"2021-12-31","value":-9676500000,"profit":false},{"date":"2022-12-31","value":-7977700000,"profit":false},{"date":"2023-12-31","value":-9590400000,"profit":false}]
Income From Continuous Operations(207.76M)(103.77M)(96.77M)(79.78M)(95.90M)[{"date":"2019-12-31","value":-20775700000,"profit":false},{"date":"2020-12-31","value":-10377300000,"profit":false},{"date":"2021-12-31","value":-9676500000,"profit":false},{"date":"2022-12-31","value":-7977700000,"profit":false},{"date":"2023-12-31","value":-9590400000,"profit":false}]
Income From Discontinued Operations(116.16M)(66.75M)4.60M108.09M-[{"date":"2019-12-31","value":-107.46,"profit":false},{"date":"2020-12-31","value":-61.75,"profit":false},{"date":"2021-12-31","value":4.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(207.76M)(103.77M)(96.77M)(79.78M)(95.90M)[{"date":"2019-12-31","value":-20775700000,"profit":false},{"date":"2020-12-31","value":-10377300000,"profit":false},{"date":"2021-12-31","value":-9676500000,"profit":false},{"date":"2022-12-31","value":-7977700000,"profit":false},{"date":"2023-12-31","value":-9590400000,"profit":false}]
EPS (Diluted)(1.89)(0.89)(0.47)(0.34)(0.39)[{"date":"2019-12-31","value":-189,"profit":false},{"date":"2020-12-31","value":-89,"profit":false},{"date":"2021-12-31","value":-47,"profit":false},{"date":"2022-12-31","value":-34,"profit":false},{"date":"2023-12-31","value":-39,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PGEN
Cash Ratio 1.35
Current Ratio 1.63

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PGEN
ROA (LTM) -42.32%
ROE (LTM) -129.32%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PGEN
Debt Ratio Lower is generally better. Negative is bad. 0.34
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.66

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PGEN
Trailing PE NM
Forward PE 9.14
P/S (TTM) 84.74
P/B 6.88
Price/FCF NM
EV/R 90.30
EV/Ebitda NM

FAQs

What is Precigen Inc share price today?

Precigen Inc (PGEN) share price today is $1.27

Can Indians buy Precigen Inc shares?

Yes, Indians can buy shares of Precigen Inc (PGEN) on Vested. To buy Precigen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PGEN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Precigen Inc be purchased?

Yes, you can purchase fractional shares of Precigen Inc (PGEN) via the Vested app. You can start investing in Precigen Inc (PGEN) with a minimum investment of $1.

How to invest in Precigen Inc shares from India?

You can invest in shares of Precigen Inc (PGEN) via Vested in three simple steps:

  • Click on Sign Up or Invest in PGEN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Precigen Inc shares
What is Precigen Inc 52-week high and low stock price?

The 52-week high price of Precigen Inc (PGEN) is $1.93. The 52-week low price of Precigen Inc (PGEN) is $0.65.

What is Precigen Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Precigen Inc (PGEN) is 6.88

What is the Market Cap of Precigen Inc?

The market capitalization of Precigen Inc (PGEN) is $374.87M

What is Precigen Inc’s stock symbol?

The stock symbol (or ticker) of Precigen Inc is PGEN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top